Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).

Exclusion Criteria

• •Known severe hypersensitivity to aumolertinib or any of the excipients of this product.
• •Had had previous chemotherapy, radiotherapy, or agents directed at the HER axis (e.g. erlotinib, gefitinib, cetuximab, trastuzumab).
• •Evidence of clinically active interstitial lung disease.
• •Eye inflammation not fully controlled or conditions predisposing the subject to this.
• •Inability to comply with protocol or study procedures.
• •A serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study.
• •A serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease.
• •History of another malignancy in the last 5 years with the exception of the following: other malignancies cured by surgery alone and having a continuous disease-free interval of 5 years are permitted. Cured basal cell carcinoma of the skin and cured in situ carcinoma of the uterine cervix are permitted.
• •Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease).
• •Patient who has active serious infection (e.g. pyrexia of or 38.0℃ over)
• •Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
• •Women who are pregnant or nursing.
• •Ingredients mixed with small cell lung cancer patients.
• •History of neurologic or psychiatric disorders.